In Vitro Metabolism by Aldehyde Oxidase Leads to Poor Pharmacokinetic Profile in Rats for c-Met Inhibitor MET401
- 82 Downloads
Background and Objectives
MET401 is a potent and selective c-Met inhibitor with a novel triazolopyrimidine scaffold. The aim of this study was to determine the pharmacokinetic profile of MET401 in preclinical species, and to identify the metabolic soft spot and enzyme involved, in order to help medicinal chemists to modify the compound to improve the pharmacokinetic profile.
A metabolite identification study was performed in different liver fractions from various species. Chemical inhibition with selective cytochrome P450 (CYP) and molybdenum hydroxylase inhibitors was carried out to identify the enzyme involved. The deuterium substitution strategy was adopted to reduce metabolism. Pharmacokinetic studies were performed in rats to confirm the effect.
Although M-2 is a minor metabolite in liver microsomal incubations, it became the predominant metabolite in incubations with liver S9, cytosol, hepatocytes and rat pharmacokinetic study. M-2 was synthesized enzymatically and the structure was identified as a mono-oxidation on the triazolopyrimidine moiety. The M-2 formation was ascribed to aldehyde oxidase (AO)-mediated metabolism based on the following evidence—M-2 production was NADPH independent, pan-CYP inhibitor 1-aminobenzotriazole and xanthine oxidase inhibitor allopurinol did not inhibit M-2 formation, and AO inhibitors menadione and raloxifene inhibited M-2 formation. The deuterated analog MET763 demonstrated an improved pharmacokinetic profile with lower clearance, longer terminal half-life and double oral exposure compared with MET401 in rats.
These results indicate that the main metabolic pathway of MET401 is AO-mediated metabolism, which leads to poor in vivo pharmacokinetic profiles in rodents. The deuterium substitution strategy could be used to reduce AO-mediated metabolism liability.
We thank Novartis c-Met project team members, especially Global Discovery Chemistry Shanghai colleagues for their contributions.
Compliance with Ethical Standards
No source of funding.
Conflict of interest
All authors were or still are Novartis employee.
All animal studies were in accordance with the ethical standards of the institution or practice at which the studies were conducted. All animal study procedures were approved by animal care and use committees before the studies were initiated.
- 8.Zhao F, Zhang J, Zhang L, Hao Y, Shi C, Xia G, et al. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal–epithelial transition factor (c-Met) protein kinase. Bioorg Med Chem. 2016;24:4281–90.CrossRefGoogle Scholar
- 11.Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for tre. J Med Chem. 2014;57:7577–89.CrossRefGoogle Scholar
- 12.Cui JJ, Shen H, Tran-Dubé M, Nambu M, McTigue M, Grodsky N, et al. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial regeneration in rats. J Med Chem. 2013;56:6651–65.CrossRefGoogle Scholar
- 18.Massey V, Komai H, Palmer G, Elion GB. On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines. J Biol Chem. 1970;245:2837–44.Google Scholar
- 39.Calabrese CR, Loadman PM, Lim LS, Bibby MC, Double JA, Brown JE, et al. In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans. Drug Metab Dispos. 1999;27:240–5.Google Scholar
- 45.Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, et al. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization. Eur J Med Chem. 2017;134:147–58.CrossRefGoogle Scholar
- 46.Su WG. Discovery, preclinical and early clinical evaluation of volitinib: a potent and selective c-Met kinase inhibitor. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, April 5–9. San Diego: AACR; 2014. https://www.hmplglobal.com/en/publications/presentation-on-volitinib-hmpl-504-at-aacr-2014/